Zai Lab (ZLAB, Financial) has received a significant boost as the FDA awarded fast track designation to its innovative Delta-like ligand antibody-drug conjugate, ZL-1310. This promising treatment is targeted at extensive-stage small cell lung cancer (SCLC). Currently, ZL-1310 is undergoing a global Phase 1a/1b clinical trial. Previously, the FDA granted it Orphan Drug status, highlighting its potential in addressing unmet medical needs in SCLC. The company is set to share further data from this research at the 2025 American Society of Clinical Oncology annual meeting, marking another step forward in its development process.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.